Supernus Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary

Supernus Pharmaceuticals

01/03/2023 03:43

* Supernus Pharmaceuticals Inc  SUPN.OQ  reported quarterly
adjusted earnings of 43 cents​​ per share for the quarter ended
in December. The mean expectation of four analysts for the
quarter was for earnings of 68 cents per share.
    * Revenue rose 5.2% to $167.33 million from a year ago;
analysts
expected $180.38 million. 
    * Supernus Pharmaceuticals Inc's reported EPS for the
quarter was
43 cents​.
    * The mean earnings estimate of analysts had risen by
about 2.3%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Supernus Pharmaceuticals Inc shares had risen by 6.4% this
quarter.
    * The company reported quarterly net income of $25.48
million.
    * Wall Street's median 12-month price target for Supernus
Pharmaceuticals Inc is $44.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data March 1
at 03:43 a.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2022      0.68           0.43           Missed
 Sep. 30 2022      0.36           0.03           Missed
 Jun. 30 2022      0.29           0.14           Missed
 Mar. 31 2022      0.24           0.43           Beat